Last updated: May 13, 2026
IDAMYCIN PFS suppliers: who manufactures and supplies Idamycin PFS (idarubicin) in finished form and for generic supply
Executive summary: “IDAMYCIN PFS” is a brand of idarubicin supplied as a prescription drug in a premixed single-dose/ready-to-use parenteral presentation. Finished-dose supply in the US is typically handled by the brand owner and contract manufacturing networks; however, supplier identification requires the drug’s FDA label “Manufactured for/By” and the Orange Book listed drug (RLD) listing for the exact NDC and dosage strength. Without the NDC(s) and the specific package size/strength corresponding to “IDAMYCIN PFS,” a complete and accurate supplier map cannot be produced.
What company makes and supplies IDAMYCIN PFS (idarubicin) in the US?
Featured snippet: The supplier for “IDAMYCIN PFS” is shown on the product label under “Manufactured for” and “Manufactured by” for the exact NDC/strength.
What label fields identify the true supplier
- “Manufactured for” (brand/marketing authorization holder)
- “Manufactured by” (site and legal manufacturer)
- “Distributed by” (distribution role)
- Lot release site (sometimes different from packaging site)
Why NDC matching matters
“IDAMYCIN PFS” can exist across multiple strengths and pack configurations. Supplier sites and legal entities can differ by:
- strength
- vial size
- packaging configuration (kit vs vial)
- change in contract manufacturing over time
Which NDCs correspond to IDAMYCIN PFS and how does that change the supplier list?
Featured snippet: Suppliers are mapped by NDC-level granularity; different NDCs can list different manufacturing/packaging sites even when the active ingredient is the same.
NDC-level supplier map (what to extract)
For each NDC associated with IDAMYCIN PFS, extract:
- label “Manufactured for/By”
- site address (if present)
- packaging-only vs manufacturing site (if described)
Common supplier transition pattern
Brand parenteral oncology products often shift between:
- original manufacturer
- contract manufacturer
- contract packaging vendor
- relabeling distributor during lifecycle changes
What is the Orange Book status of IDAMYCIN PFS and who is the RLD applicant?
Featured snippet: The RLD applicant and any listed strengths correspond to the Orange Book listed drug record for idarubicin’s NDC.
How to use Orange Book to identify supply-side IP holders
Orange Book fields support two practical supplier questions:
- who holds the application (applicant)
- whether there are qualifying generics or ANDAs that can indicate alternate supply channels
Patent and exclusivity relevance to supply
Even when generics are not yet marketed, Orange Book can show:
- whether the RLD has active patents
- whether exclusivities could affect entry timing and sourcing
Are there generic or authorized alternative suppliers for idarubicin PFS that compete with IDAMYCIN PFS?
Featured snippet: Alternative suppliers usually appear as ANDA generics that reference the RLD and are marketed under their own labeler/NDC set.
How generic presence changes the supplier landscape
If ANDA products exist for the same dosage form and strength:
- hospital procurement may substitute among NDCs
- supplier lists expand from brand manufacturer only to multiple ANDA labelers
- contracting shifts from brand site to multiple secondary sources
What “PFS” implies for substitution
Substitution risk depends on whether the comparator is:
- the same concentration and volume
- the same administration setup
- the same dosage form classification under FDA
Which suppliers manufacture the underlying active ingredient vs finished idarubicin PFS?
Featured snippet: The label supplier is the finished-dose manufacturer; the active ingredient manufacturer is usually not shown on the US label.
Typical split in parenteral oncology manufacturing
- API manufacturer: idarubicin synthesis site
- Finished-dose manufacturer: fills, formulates, aseptically processes, and sterilizes
- Packaging site: secondary packaging, labeling, kit configuration
- Distribution: wholesaler networks and specialty distributors
Why finished-dose identification is the key compliance answer
For procurement, cold-chain, sterility controls, and traceability, the finished-dose manufacturer is the operational supplier.
What patent estates protect IDAMYCIN PFS and do they restrict supplier entry?
Featured snippet: Patent and exclusivity status can restrict generic entry and influence whether supply is limited to the RLD during lifecycle.
How patent strength affects sourcing
- active patents increase the likelihood of stays or limited entry
- formulation or method-of-use patents can restrict “workalike” formulations
- manufacturing patents can affect ability to switch to alternative sites
What to check for supplier risk
- whether any Paragraph IV litigation exists involving idarubicin PFS
- whether settlements impose effective entry dates
- whether supply disruptions increase reliance on current manufacturers
How to build a definitive supplier list for IDAMYCIN PFS in practice
Featured snippet: A definitive list requires (1) NDC-to-product label mapping and (2) FDA Orange Book RLD applicant mapping.
Deliverables procurement teams need
- Supplier legal entity per NDC
- Manufacturing site address per NDC
- Packaging/labeling role per NDC
- Orange Book applicant (RLD) and patent list for that NDC
Key Takeaways
- “IDAMYCIN PFS” supplier identification is NDC-specific and is determined from the FDA label manufacturing/distribution fields for the exact strength and pack.
- Orange Book status helps confirm the RLD applicant and whether other marketed versions exist, which expands the supplier landscape.
- Without the exact NDC(s) or label strength/pack identifier for the “IDAMYCIN PFS” product in scope, a complete supplier list cannot be generated accurately.
FAQs
-
How do I identify the real manufacturer of a branded PFS drug like IDAMYCIN from the label?
By reading the “Manufactured for” and “Manufactured by” fields on the specific NDC label.
-
Do supplier sites differ by strength for the same idarubicin brand?
Yes, manufacturing and packaging roles often differ across NDCs even within the same brand presentation.
-
How does Orange Book listing affect supply competition for idarubicin?
It identifies the RLD applicant and can show whether authorized generics exist that broaden supply.
-
What role do contract manufacturers and packaging vendors play in IDAMYCIN PFS supply?
They may handle aseptic filling/sterile processing and secondary packaging even if the brand labeler remains unchanged.
-
Can generic idarubicin PFS products substitute for IDAMYCIN PFS at hospitals?
Substitution depends on matching concentration/volume, dosage-form classification, and approved labeling for the exact NDC/strength.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Drug Products).
- FDA. Drug Labeling (e.g., DailyMed) for idarubicin products.
